GO
Loading...

Medicine

More

  • April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as sales of several key products fell short of Wall Street estimates, with its big-selling rheumatoid arthritis drug Enbrel particularly hard hit by inventory stocking by wholesalers late last year.

  • April 22- Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.

  • April 22- Gilead Sciences Inc, whose pricing policy ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.

  • *Novartis to buy GSK's oncology assets for $14.5 bln. The deals, which include Novartis buying GSK's cancer drugs and GSK acquiring Novartis' vaccines business, came hot on the heels of a newspaper report that AstraZeneca had turned down a $101 billion bid approach from Pfizer- a story that sent shares across the sector surging.

  • *Novartis to buy GSK's oncology assets for $14.5 bln. *Lilly to buy Novartis' animal health arm for $5.4 bln.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.

  • Sarepta muscle drug faces challenges     Monday, 21 Apr 2014 | 2:04 PM ET

    Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.

  • *Plans to file for eteplirsen approval by end of 2014. April 21- Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug.

  • Weed vending in Colorado     Monday, 21 Apr 2014 | 10:21 AM ET

    As marijuana safety concerns grow, Stephen Shearin, Tranzbyte COO, discusses his company's age verification marijuana vending machine for medicinal users.

  • The company hit a roadblock late last year when the health regulator said the design and goals of the previous trial may not be sufficient, citing new data on DMD and the failed trial of a competing drug made by Prosensa Holding NV.

  • AstraZeneca cancer pipeline seen as draw for Pfizer Monday, 21 Apr 2014 | 6:55 AM ET

    LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

  • Saudi health minister sacked amid virus deaths Monday, 21 Apr 2014 | 5:04 AM ET

    RIYADH, Saudi Arabia— Saudi Arabia's King Abdullah sacked the country's health minister on Monday amid a spike in deaths and infections from the virus known as the Middle East respiratory syndrome, or MERS.

  • $14M awarded in suit linking contraceptive, stroke Saturday, 19 Apr 2014 | 10:51 AM ET

    CHICAGO— A jury has awarded $14 million to a suburban Chicago woman who said in a lawsuit that she suffered a debilitating stroke after taking the birth control drug Yasmin. Friday's verdict came after a two-week trial in Cook County Circuit Court. A $2.5 million settlement in the same matter was reached a month ago with the hospital, Resurrection Medical Center.

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • Doctors urged to weigh costs in treatment decisions Friday, 18 Apr 2014 | 12:00 AM ET

    Some medical groups now want doctors to consider both the effectiveness and costs of treatment options.

  • Merck's ragweed pollen allergy drug gets U.S. approval Thursday, 17 Apr 2014 | 3:00 PM ET

    April 17- The U.S. Food and Drug Administration has approved Merck& Co's pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis.

  • New discovery in $1.7 billion IVF business     Thursday, 17 Apr 2014 | 2:57 PM ET

    CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.

  • April 17- The U.S. Food and Drug Administration warned that a surgical procedure used to mince uterine fibroids and remove them through a tiny abdominal incision could spread cancer tissue beyond the uterus in women with undetected uterine cancer.

  • FDA warns of cancer risk with fibroid procedure Thursday, 17 Apr 2014 | 1:05 PM ET

    WASHINGTON— The Food and Drug Administration is warning women that a surgical procedure used to eliminate growths in the uterus could inadvertently spread cancer to other parts of the body.

Most Popular Video

Wednesday, 23 Apr 2014 | 11:30 AM ET

Saving for retirement is about to get a whole lot more complicated. CNBC's Allison Linn reports on the "new normal" that may mean those planning to retire in 20-25 years may have to get used to a slightly lower standard of living than in the pension heyday.

Wednesday, 23 Apr 2014 | 11:00 AM ET

An 11th person was arrested yesterday in connection with a Philadelphia area drug ring where police say high school and college students were the targets.

Wednesday, 23 Apr 2014 | 10:17 AM ET

Former Apple CEO John Sculley, discusses Apple innovation and if the DNA of Apple has changed under CEO Tim Cook. Sculley also weighs in on earnings expectations for the tech giant.